Portosystemic shunting is the key driver of portal/splanchnic vein thrombosis development
A Wunderbaldinger(Medical University of Vienna), Mattias Mandorfer(Medical University of Vienna), Lukas Hartl(Medical University of Vienna), Natalia Dominik(National Hospital for Neurology and Neurosurgery), Bernhard Scheiner(Medical University of Vienna), Joana Calvão(University of Coimbra), Michael Trauner(Medical University of Vienna), Gero Kramer(Memorial Sloan Kettering Cancer Center), B Simbrunner(Medical University of Vienna), Thomas Reiberger(ERN GUARD-Heart), M Hintersteininger(Medical University of Vienna), Benedikt Hofer(Austrian Academy of Sciences), Albert Friedrich Stättermayer(Medical University of Vienna), Mathias Jachs(Medical University of Vienna), Christian Sebesta(Donauspital), Lorenz Balcar(Medical University of Vienna), G Semmler(Medical University of Vienna), Paul Thöne(Medical University of Vienna)
Cited by 0
Related Papers
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
|Journal of Hepatology|2021|309
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
|Journal of Hepatology|2024|239